Active, not recruitingPHASE1, PHASE2NCT01318317

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Studying Indolent B-cell non-Hodgkin lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
City of Hope Medical Center
Principal Investigator
Elizabeth L Budde, MD,PhD
City of Hope Medical Center
Intervention
Autologous Hematopoietic Stem Cell Transplantation(procedure)
Enrollment
8 enrolled
Eligibility
18 years · All sexes
Timeline
20112026

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01318317 on ClinicalTrials.gov

Other trials for Indolent B-cell non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Indolent B-cell non-Hodgkin lymphoma

← Back to all trials